SS-31 is a tiny engineered peptide — just four amino acids (the building blocks of proteins) — built to do one unusual thing: pile up inside mitochondria, the microscopic engines that power almost every cell. Its formal name is elamipretide, and it is the most clinically advanced member of a family called the Szeto–Schiller (SS) peptides. In September 2025 it became the first mitochondria-targeted drug the FDA has ever approved, for a rare disease called Barth syndrome5.
In plain terms: a small peptide with a real address label for the cell’s power plants — with one approved use and a genuinely mixed trial record everywhere else.
What it is
Mitochondria are the organelles (specialised parts of a cell) that turn food and oxygen into usable energy. When they fail, high-energy tissues suffer first — muscle, heart, brain, kidney.
SS-31 is a four-residue peptide designed to protect those failing mitochondria. It carries a pattern of positive charges, and the inside membrane of a mitochondrion is strongly negative, so the peptide is pulled straight to it1. The result is that SS-31 concentrates inside mitochondria far more than in the rest of the cell — a targeting trick most drugs cannot manage.
How it is thought to work
The key partner is a lipid (a fat molecule) called cardiolipin. Cardiolipin sits almost exclusively on the inner mitochondrial membrane, where it helps organise the "electron transport chain" — the assembly line that actually makes energy — into tidy, efficient clusters.
SS-31 binds cardiolipin1. By doing so it is reported to:
- Stabilise the folds (cristae) of the inner membrane, keeping the energy assembly line intact.
- Protect cytochrome c, a component that normally carries electrons; when cardiolipin goes wrong, cytochrome c can turn destructive, and SS-31 helps prevent that switch.
- Lower the leak of reactive oxygen species — the damaging by-products ("free radicals") that failing mitochondria overproduce.
In plain terms: it acts like a stabiliser clipped onto the power plant’s wiring, so the plant makes energy cleanly instead of throwing off sparks. Treat that as a well-worked-out mechanism — the harder question is whether it changes how patients feel.
Pharmacokinetics and half-life
SS-31 is given by subcutaneous (under-the-skin) injection in trials. It is absorbed quickly and cleared from the blood fairly fast — a reported plasma half-life (the time for half a dose to leave the bloodstream) of roughly 4 hours. That number comes from pharmacokinetic reporting rather than a single landmark paper, so treat it as an approximate figure.
There is a twist that matters. Because the peptide binds and holds inside mitochondria-rich tissue, its effect on those tissues can outlast its level in the blood. So a short blood half-life does not mean a short biological effect.
What the trials actually found
This is where honesty earns its keep. SS-31 has a real, sizeable human trial programme — and the results genuinely cut both ways. Note the model and outcome in each row.
| Trial (cited) | Model / level | Key result | Year |
|---|---|---|---|
| Szeto review1 | Review (cell + animal) | Laid out the cardiolipin-binding mechanism; strong preclinical energy-recovery signals | 2014 |
| PROGRESS-HF, Butler et al.3 | Human, n=71 (heart failure) | Missed primary endpoint — no significant change in left-ventricular volume at 4 weeks | 2020 |
| TAZPOWER, Reid Thompson et al.4 | Human, n=12 (Barth syndrome) | Crossover phase missed its main mark, but the open-label extension showed functional gains that supported later approval | 2021 |
| MMPOWER-3, Karaa et al.2 | Human, n=218 (mitochondrial myopathy) | Missed both primary endpoints — no significant gain in 6-minute walk distance or fatigue | 2023 |
The pattern: a compelling mechanism and one hard-won approval for an ultra-rare disease, alongside two prominent trials that did not hit their targets. In the heart-failure trial, elamipretide was well tolerated but did not improve heart function at 4 weeks3. In the largest myopathy trial, 218 adults saw no significant benefit on walking distance or fatigue versus placebo2.
In plain terms: this is not a compound with a clean win record. It is a compound with real human data — some positive, several negative — and that mix is the honest headline.
The approved use
In September 2025 the FDA granted elamipretide accelerated approval, branded Forzinity, to improve muscle strength in people with Barth syndrome weighing at least 30 kg5. Barth syndrome is a rare, life-limiting genetic disease of cardiolipin metabolism affecting only around 150 people in the US — a fitting target given how SS-31 works. "Accelerated approval" means the benefit is considered likely but still has to be confirmed in further trials.
This is the crucial framing line: SS-31 is now an approved medicine for one narrow, rare disease — and remains investigational for the broader anti-ageing and performance uses it is often discussed for. Those broader uses rest on mechanism and preclinical work, not on approval.
Latest research
- FDA accelerated approval (September 2025). Elamipretide became the first mitochondria-targeted therapy approved, for Barth syndrome5.
- MMPOWER-3 (2023) remains the sobering data point: in 218 adults with primary mitochondrial myopathy, elamipretide missed both primary endpoints2. A later post-hoc analysis suggested people with certain (nuclear-DNA) genetic subtypes may have responded better — a hypothesis for future trials, not a proven benefit.
- Long-term Barth data from the TAZPOWER open-label extension continued to accrue, tracking muscle and heart-function measures over years4.
The short version
SS-31 (elamipretide) is a four-amino-acid peptide engineered to concentrate inside mitochondria and bind cardiolipin, stabilising the cell’s energy machinery1. It earned FDA accelerated approval for Barth syndrome in 2025 — a genuine first — but its major trials in mitochondrial myopathy and heart failure missed their primary endpoints23. Real human data, honestly mixed. Educational overview only, not medical advice. For context, see what are research peptides.